Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
March 04, 2025 | 04:58
Telix Pharmaceuticals Limited invites investors to join a webinar showcasing the Company's late-stage and next-generation radiotherapeutic candidates in urologic oncology.
Illuccix® Receives European Approval
January 17, 2025 | 05:14
Telix Pharmaceuticals Limited today announces that it has received a positive decision on the Marketing Authorization Application for its prostate cancer PET imaging agent Illuccix®, which was submitted in Europe via a decentralized procedure (DCP).
FDA accepts new drug application and grants priority review for TLX101-CDx brain cancer imaging agent
October 24, 2024 | 05:02
Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has accepted the new drug application for TLX101-CDx.
Telix Files Form 20-F Registration Statement for Nasdaq ADS
October 18, 2024 | 04:32
Telix Pharmaceuticals Limited announces that it has publicly filed a Form 20-F registration statement with the United States Securities and Exchange Commission relating to a proposed listing of American Depository Shares, representing the Company's ordinary shares, on the Nasdaq Stock Market.
Mobile Version